Molecular Partners backs FY24 total expenses view of of CHF 65M-CHF 70M

For the full year 2024, at constant exchange rates, the Company reiterates its guidance for total expenses of CHF 65-70 million. Approximately CHF 7 million of this will be non-cash effective costs for share-based payments, pension accounting and depreciation. This guidance does not include any potential receipts from R&D collaborators. With CHF 143.6 million in cash and short-term time deposits and no debt as of September 30 the Company expects to be funded into 2027, excluding any potential receipts from R&D collaborators…In the last quarter we continued to execute our plan to bring our first Radio-DARPin program to IND submission, and into the clinics. DLL3 remains a highly interesting target that is gaining significant attention. Our team presented additional preclinical data showing that MP0712 is safe and efficacious in a highly relevant tumor model, with DLL3 expression levels matching those in human tumors,” said Patrick Amstutz, Ph.D., Molecular Partners (MOLN)’ Chief Executive Officer. “In addition, we strengthened our relationship with our partner Orano Med, ensuring that both parties will have the opportunity to bring two Radio-DARPin products to market, for a total of four. Lastly our recent capital raise allows us additional financial flexibility into 2027 with participation from new, specialized investors and supportive existing investors.”